A reterospective study assessing the physician reason(s) for initiating Canakinumab and characterize the clinical and treatment profiles of Systemic Juvenile Idiopathic Arthritis patients in US clinical practice
Latest Information Update: 05 Feb 2020
At a glance
- Drugs Canakinumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Therapeutic Use
Most Recent Events
- 05 Feb 2020 New trial record